Dizal (Jiangsu) Pharmaceutical Company Description

Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases.

It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors.

The company was founded in 2017 and is based in Shanghai, China.

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Country	China
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
Employees	581
CEO	Zhang Xiaolin

Contact Details

Address: 199 Liangjing Rd Shanghai, 201203 China
Phone	86 21 6109 7800
Website	dizalpharma.com

Stock Details

Ticker Symbol	688192
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Lyu Hongbin M.B.A.	Accounting Supervisor, Chief Financial Officer and Board Secretary
Dr. Qingbei Zeng	Deputy GM and Chief Scientist
Dr. Zhenfan Yang M.D., Ph.D.	Deputy GM and Chief Medical Officer
Qingyi Wu	Deputy GM and Chief Commercial Officer
Dr. Shih-Ying Chang Ph.D.	Deputy GM and Vice President of Chemistry, Manufacturing and Control
Dr. Honchung Tsui	Deputy General Manager
Kan Chen	Senior Director
Zhiwei Zhang	Deputy General Manager
Suqin Chen	Deputy General Manager
Weijun Qiao	Vice President